TY - JOUR
T1 - Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C
AU - Romero-Gómez, Manuel
AU - Fernández-Rodríguez, Conrado M.
AU - Andrade, Raúl J.
AU - Diago, Moisés
AU - Alonso, Sonia
AU - Planas, Ramón
AU - Solá, Ricard
AU - Pons, José A.
AU - Salmerón, Javier
AU - Barcena, Rafael
AU - Perez, Ramón
AU - Carmona, Isabel
AU - Durán, Santiago
PY - 2008/5
Y1 - 2008/5
N2 - Background/Aims: To investigate the effect of sustained virological response (SVR) on impaired fasting glucose (IFG) and/or type 2 diabetes (T2DM); to assess the influence of glucose abnormalities on the SVR rate. Methods: 1059 patients with chronic HCV; normal glucose (< 100 mg/dl) in 734, IFG (between 100 and 125 mg/dl) in 218, and T2DM (≥126 mg/dl) in 107 cases, were treated with interferon plus ribavirin over 24 or 48 weeks, depending on viral genotype. Results: The SVR rate was lower in patients with IFG and/or T2DM than in patients with normal glucose concentrations [143/325 (44%) vs. 432/734 (58.8%); P = 0.002]. In the follow-up, abnormal glucose concentrations were observed in 74 of 304 (24.3%) non-responders and in 49 of 430 (11.4%) sustained responders (log-rank: 13.8; P = 0.00002). Reverse stepwise logistic regression analysis identified the independent variables predictive of IFG or T2DM development as: sustained response (OR: 0.44; 95%CI = 0.20-0.97; P = 0.004) and fibrosis stage (OR: 1.46; 95%CI = 1.06-2.01;P = 0.02). Family history of DM, steatosis, gender, HCV viral load, genotype, triglycerides, cholesterol and BMI did not enter the multivariate analysis equation. Conclusions: SVR reduces the risk of IFG and/or T2DM development in patients with chronic hepatitis C while altered glucose metabolism impairs sustained response to viral treatment.
AB - Background/Aims: To investigate the effect of sustained virological response (SVR) on impaired fasting glucose (IFG) and/or type 2 diabetes (T2DM); to assess the influence of glucose abnormalities on the SVR rate. Methods: 1059 patients with chronic HCV; normal glucose (< 100 mg/dl) in 734, IFG (between 100 and 125 mg/dl) in 218, and T2DM (≥126 mg/dl) in 107 cases, were treated with interferon plus ribavirin over 24 or 48 weeks, depending on viral genotype. Results: The SVR rate was lower in patients with IFG and/or T2DM than in patients with normal glucose concentrations [143/325 (44%) vs. 432/734 (58.8%); P = 0.002]. In the follow-up, abnormal glucose concentrations were observed in 74 of 304 (24.3%) non-responders and in 49 of 430 (11.4%) sustained responders (log-rank: 13.8; P = 0.00002). Reverse stepwise logistic regression analysis identified the independent variables predictive of IFG or T2DM development as: sustained response (OR: 0.44; 95%CI = 0.20-0.97; P = 0.004) and fibrosis stage (OR: 1.46; 95%CI = 1.06-2.01;P = 0.02). Family history of DM, steatosis, gender, HCV viral load, genotype, triglycerides, cholesterol and BMI did not enter the multivariate analysis equation. Conclusions: SVR reduces the risk of IFG and/or T2DM development in patients with chronic hepatitis C while altered glucose metabolism impairs sustained response to viral treatment.
KW - Impaired fasting glucose
KW - Insulin resistance
KW - Peginterferon
KW - Ribavirin
KW - Sustained virological response
KW - Type 2 diabetes mellitus
UR - http://www.scopus.com/inward/record.url?scp=40949151098&partnerID=8YFLogxK
U2 - 10.1016/j.jhep.2007.11.022
DO - 10.1016/j.jhep.2007.11.022
M3 - Article
C2 - 18308416
AN - SCOPUS:40949151098
SN - 0168-8278
VL - 48
SP - 721
EP - 727
JO - Journal of Hepatology
JF - Journal of Hepatology
IS - 5
ER -